// App-Quantinova.ai

30P : Treatment-induced hypoxia attenuates enzalutamide response and promotes resistance in pre-clinical models of prostate cancer

Researchers

Presenter

  • P.J.Maxwell

Principal Investigators

  • M.Labonte

  • M.McKechnie

  • O.Duddy

  • C.Armstrong

  • C.W.Ong

  • A.Zoubeidi

  • J.Worthington

  • D.Waugh

Medical Centers

  • Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Axis Bioservices, Axis Bioservices, Coleraine, UK

Locations

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved